The Endocrine Society has developed clinical practice guidelines for the endocrine treatment of transsexual persons. The guidelines aim to provide safe and effective hormone therapy for individuals seeking to develop the physical characteristics of their desired gender. The guidelines emphasize the importance of a mental health professional (MHP) in recommending and overseeing endocrine treatment, as well as the need for a thorough evaluation of the individual's mental health and readiness for treatment. Prepubertal children are not recommended for endocrine treatment due to the inability to make a definitive diagnosis of transsexualism. Adolescents with Tanner stage 2 are recommended to start puberty suppression with GnRH analogs, followed by cross-sex hormones at age 16. For adults, hormone therapy should maintain sex hormone levels within the normal range for the desired gender and monitor for known risks. The guidelines also emphasize the importance of regular clinical and laboratory monitoring, fertility counseling, and long-term care for transsexual individuals. The guidelines recommend that hormone-treated adolescents be referred for surgery when they have achieved a satisfactory social role change, are satisfied with hormonal effects, and desire definitive surgical changes. Surgery should be deferred until the individual is at least 18 years old. The guidelines also highlight the importance of evaluating and addressing medical conditions that may be exacerbated by hormone therapy before treatment begins. The guidelines are based on evidence from existing medical literature and clinical experience, and they emphasize the need for ongoing collaboration between mental health professionals and endocrinologists to ensure the best possible outcomes for transsexual individuals.The Endocrine Society has developed clinical practice guidelines for the endocrine treatment of transsexual persons. The guidelines aim to provide safe and effective hormone therapy for individuals seeking to develop the physical characteristics of their desired gender. The guidelines emphasize the importance of a mental health professional (MHP) in recommending and overseeing endocrine treatment, as well as the need for a thorough evaluation of the individual's mental health and readiness for treatment. Prepubertal children are not recommended for endocrine treatment due to the inability to make a definitive diagnosis of transsexualism. Adolescents with Tanner stage 2 are recommended to start puberty suppression with GnRH analogs, followed by cross-sex hormones at age 16. For adults, hormone therapy should maintain sex hormone levels within the normal range for the desired gender and monitor for known risks. The guidelines also emphasize the importance of regular clinical and laboratory monitoring, fertility counseling, and long-term care for transsexual individuals. The guidelines recommend that hormone-treated adolescents be referred for surgery when they have achieved a satisfactory social role change, are satisfied with hormonal effects, and desire definitive surgical changes. Surgery should be deferred until the individual is at least 18 years old. The guidelines also highlight the importance of evaluating and addressing medical conditions that may be exacerbated by hormone therapy before treatment begins. The guidelines are based on evidence from existing medical literature and clinical experience, and they emphasize the need for ongoing collaboration between mental health professionals and endocrinologists to ensure the best possible outcomes for transsexual individuals.